Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Citizens Business Bank

Citizens Business Bank lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 6,125 shares of the biopharmaceutical company’s stock after acquiring an additional 114 shares during the period. Citizens Business Bank’s holdings in Regeneron Pharmaceuticals were worth $3,216,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Catawba River Capital boosted its stake in shares of Regeneron Pharmaceuticals by 206.9% during the 2nd quarter. Catawba River Capital now owns 29,676 shares of the biopharmaceutical company’s stock worth $15,580,000 after acquiring an additional 20,006 shares in the last quarter. Private Trust Co. NA boosted its stake in shares of Regeneron Pharmaceuticals by 16.5% during the 2nd quarter. Private Trust Co. NA now owns 191 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 27 shares in the last quarter. Applied Finance Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 16.1% during the 2nd quarter. Applied Finance Capital Management LLC now owns 22,983 shares of the biopharmaceutical company’s stock worth $12,066,000 after acquiring an additional 3,190 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 6.3% during the 2nd quarter. Nordea Investment Management AB now owns 46,988 shares of the biopharmaceutical company’s stock worth $24,521,000 after acquiring an additional 2,768 shares in the last quarter. Finally, S Bank Fund Management Ltd boosted its stake in shares of Regeneron Pharmaceuticals by 12.0% during the 2nd quarter. S Bank Fund Management Ltd now owns 1,163 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 125 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $578.05 on Friday. The stock has a 50 day moving average of $574.64 and a two-hundred day moving average of $562.89. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,002.69. The company has a market capitalization of $61.27 billion, a P/E ratio of 14.57, a P/E/G ratio of 1.77 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research note on Monday, August 4th. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.